All In Biotech

Drug Trial Radar · NCT01462422

Misoprostol for Secondary Prevention of Postpartum Hemorrhage at the Community Level in India

Two Community Strategies Comparing Use of Misoprostol for Secondary Prevention to Primary Prevention for Postpartum Hemorrhage: A Randomized Cluster Non-Inferiority Study in Bijapur District, Karnataka, India

Last checked: Nov 20, 2026Latest source record: Jun 16, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 3,032 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

3,032

Actual

Start

Dec 2011

Primary completion

Mar 2014

Study completion Mar 2014

Sponsor

Lead sponsor
Gynuity Health ProjectsAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Sri B. M. Patil Medical College, Bijapur, Karnataka, India; Jawaharlal Nehru Medical College; University of Illinois Chicago; University of California, San Francisco
First posted
Oct 31, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Health services research
Who can join
Female only, from 15 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study compares two community-level strategies: selective administration of 800 mcg sublingual misoprostol to women at 350 mL blood loss for secondary prevention of postpartum hemorrhage (PPH) with universal use of 600 mcg oral misoprostol at the time of delivery for primary prevention of PPH. The study hypothesizes that at community-level births, secondary prevention for women is non-inferior (based on clinical parameters) to universal prophylaxis provided to women for primary prevention of PPH. This cluster-design non-inferiority trial has the potential to inform service delivery programs on clinical outcomes, program feasibility, cost and acceptability of two different community models of PPH care using misoprostol.

Conditions

  • Postpartum Hemorrhage

Interventions

  • MisoprostolDrug

    Selective administration of 800 mcg sublingual misoprostol to women with at least 350 mL blood loss within 1 hour following delivery

  • MisoprostolDrug

    Universal administration of 600 mcg oral misoprostol given to all women within 5 minutes of delivery of the baby

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of women with post-delivery hemoglobin ≤ 7.8 gm/dLTime frame: 72 hours (plus or minus 8 hours) after delivery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Deliveries at health sub-centers and homes

    Vijayapura, Karnataka, India

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.